Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma.

ABSTRACT:

Rationale

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer that typically affects women ages 20 to 50, presenting as an asymptomatic neck mass. Treatment with total or partial thyroidectomy shows an excellent prognosis. However, investigation of non-invasive therapeutic options with minimal adverse effects is ongoing. This study seeks to investigate the K1 cell line, which consists of PTC cells obtained from metastatic tumors of well-differentiated PTC.

Objective

Our investigation focuses on a cannabinoid-based product (named BRF1-A) and its potential anti-cancer effects through modulation of gene expression. We investigated its effects on gene expression of p53, c-Myc, and BCL-2 in K1 papillary thyroid cancer cells.

Methods

BRF1A was co-cultured wi

SUBMITTER: Taico Oliva C 

PROVIDER: S-EPMC12301603 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature